Scott T. Tagawa, MD, MS | Authors


Results of Phase I Study Reach Primary End Point for mCRPC

May 14, 2020

Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.

Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPC

July 07, 2015

Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).